Treatment of malignant sinonasal tumours with intensity-modulated radiotherapy (IMRT) and carbon ion boost (C12)

Alexandra D Jensen, Anna V Nikoghosyan, Christine Windemuth-Kieselbach, Jürgen Debus, Marc W Münter, Alexandra D Jensen, Anna V Nikoghosyan, Christine Windemuth-Kieselbach, Jürgen Debus, Marc W Münter

Abstract

Background: Most patients with cancers of the nasal cavity or paranasal sinuses are candidates of radiation therapy either due incomplete resection or technical inoperability. Local control in this disease is dose dependent but technically challenging due to close proximity of critical organs and accompanying toxicity. Modern techniques such as IMRT improve toxicity rates while local control remains unchanged. Raster-scanned carbon ion therapy with highly conformal dose distributions may allow higher doses at comparable or reduced side-effects.

Methods/design: The IMRT-HIT-SNT trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°III) and efficacy (secondary endpoint: local control, disease-free and overall survival) in the combined treatment with IMRT and carbon ion boost in 30 patients with histologically proven (≥R1-resected or inoperable) adeno-/or squamous cell carcinoma of the nasal cavity or paransal sinuses. Patients receive 24 GyE carbon ions (8 fractions) and IMRT (50 Gy at 2.0 Gy/fraction).

Discussion: The primary objective of IMRT-HIT-SNT is to evaluate toxicity and feasibility of the proposed treatment in sinonasal malignancies.

Trial registration: Clinical trial identifier NCT 01220752.

Trial registration: ClinicalTrials.gov NCT01220752.

Figures

Figure 1
Figure 1
Trial flow chart.
Figure 2
Figure 2
Follow-up.

References

    1. Muir CS, Nectoux J. Descritptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses. Clin Otolaryngol Allied Sci. 1980;5:195–211. doi: 10.1111/j.1365-2273.1980.tb01647.x.
    1. Rousch G. Epidemiology of cancer of nose and paranasal sinus carcinomas: current concepts. Head Neck Surg. 1979;2:3–11. doi: 10.1002/hed.2890020103.
    1. Madani I, Bonte K, Vakaet L, Boterberg T, De Neve W. Intensity-modulated radiotherapy for sinonasal tumors: Ghent University Hospital update. Int J Radiat Oncol Biol Phys. 2009;73:424–432. doi: 10.1016/j.ijrobp.2008.04.037.
    1. Licitra L, Locati LD, Cavina R, Garassino I, Mattavelli F, Pizzi N. et al.Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer. Ann Oncol. 2003;14:367–372. doi: 10.1093/annonc/mdg113.
    1. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. Cancer. 2001;92:3012–3029. doi: 10.1002/1097-0142(20011215)92:12<3012::AID-CNCR10131>;2-E.
    1. Parsons JT, Mendenhall WM, Mancuso AA, Cassisi NJ, Million RR. Malignant tumors of the nasal cavity and ethmoid and sphenoid sinuses. Int J Radiat Oncol Biol Phys. 1988;14:11–22. doi: 10.1016/0360-3016(88)90044-2.
    1. Shukovsky LJ, Fletcher GH. Retinal and optic nerve complications in a high dose irradiation technique of ethmoid sinus and nasal cavity. Radiology. 1972;104:629–634.
    1. Brizel DM, Light K, Zhou SM, Marks LB. Conformatl radiation therpy treatment planning reduces the dose to the optic structures for patients with tumors of the paranasal sinuses. Radiother Oncol. 1999;51:215–218. doi: 10.1016/S0167-8140(99)00043-2.
    1. Huang D, Xia P, Akazawa P, Quivey JM, Verhey LJ, Kaplan M. et al.Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:158–168. doi: 10.1016/S0360-3016(03)00080-4.
    1. Lomax AJ, Goitein M, Adams J. Intensity modulation in radiotherapy: photons versus protons in the paranasal sinus. Radiother Oncol. 2003;66:11–18.
    1. Mock U, Georg D, Bogner J, Auberger T, Pötter R. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2004;58:147–154. doi: 10.1016/S0360-3016(03)01452-4.
    1. Chen AM, Sreeraman R, Mathai M, Vijayakumar S, Purdy JA. Potential of helical tomotherapy to reduce dose to the ocular structures for patients treated for unresectable sinonasal cancer. Am J Clin Oncol. 2010. in press .
    1. Chera BS, Malyapa R, Louis D, Mendenhall WM, Li Z, Lanza DC. et al.Proton therapy for maxillary sinus carcinoma. Am J Clin Oncol. 2009;32:296–303. doi: 10.1097/COC.0b013e318187132a.
    1. Chen AM, Daly ME, Bucci MK, Xia P, Akazawa C, Quivey JM, Weinberg V. et al.Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys. 2007;69:141–147. doi: 10.1016/j.ijrobp.2007.02.031.
    1. Daly ME, Chen AM, Bucci MK, El-Sayed I, Xia P, Kapla MJ. et al.Intensity-modluated radiation therapy for malignancies of the nasal cavity and paranasal sinuses. Int J Radiat Oncol Biol Phys. 2007;67:151–157. doi: 10.1016/j.ijrobp.2006.07.1389.
    1. Hoppe BS, Wolden SL, Zelefsky MJ, Mechalakos JG, Shah JP, Kraus DH. et al.Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: technique, early outcome, and toxicity. Head Neck. 2008;30:925–932. doi: 10.1002/hed.20800.
    1. Truong MT, Kamat UR, Liebsch NJ, Curry WT, Lin DT, Barker FG. et al.Proton radiation therapy for primary sphenoid sinus malignancies: treatment outcome and prognostic factors. Head Neck. 2009;31:1297–1308. doi: 10.1002/hed.21092.
    1. Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu Aj, Wolden SL. et al.Unresectable carcinoma of the paranasal sinuses: outcome and toxicities. Int J Radiat Oncol Biol Phys. 2008;72:763–769. doi: 10.1016/j.ijrobp.2008.01.038.
    1. Snyers A, Janssens GORJ, Twickler MB, Hermus AR, Takes RP, Kappelle AC. et al.Malignant tumors of the nasal cavity and paranasal sinuses: long-term outcome and morbidity with emphasis on hypothalamic-pituary deficiency. Int j Radiat Oncol Biol Phys. 2009;73:1343–1351. doi: 10.1016/j.ijrobp.2008.07.040.
    1. Dirix P, Nuyts S, Geussens Y, Jorissen M, Vander Poorten V, Fossion E. et al.Malignancies of the nasal cavity and paranasal sinuses: long-term outcome with conventional or three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:1042–1050. doi: 10.1016/j.ijrobp.2007.04.044.
    1. Chen AM, Daly ME, El-Sayed I, Garcia J, Lee NY, Bucci MK. et al.Patterns of failure after combined-modality approaches incorporating radiotherapy for sinonasal undifferentiated carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2008;70:338–343. doi: 10.1016/j.ijrobp.2007.06.057.
    1. Thornton AF, Fitzek MM, Varvares M, Adams J, Rosenthal S, Pollock C. et al.Acelerated, hyperfractionated proton/photon irradiation for advanced paranasal sinus cancer: results of a prospective phase I-II study. Int J Radiat Oncol Biol Phys. 1998;42:222–1027.
    1. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials. 1989;10:1–10. doi: 10.1016/0197-2456(89)90015-9.
    1. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RA, Rubinstein L. et al.New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–216. doi: 10.1093/jnci/92.3.205.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel